The Office of Hematology and Oncology Products at FDA has been renamed the Office of Oncologic Diseases—a move that includes an internal reorganization of divisions, as part of modernization plans approved in September 2019.
When The Cancer Letter founder Jerry Boyd carried the first print run of his little eight page oncology newsletter into an NCAB meeting in 1973, he certainly could not have predicted that, half a century later, his experiment would branch out into this thing called “podcasts.”
